Last updated on July 2017

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma


Brief description of study

This research study will evaluate the safety and efficacy of a study drug called TGR-1202 in combination with another study drug called ublituximab with or without bendamustine and TGR-1202 alone as a possible treatment for Non-Hodgkin's Lymphoma (NHL) that has come back or that has not responded to standard treatment.

Clinical Study Identifier: NCT02793583

Contact Investigators or Research Sites near you

Start Over

TG Therapeutics Clinical Support Team

TG Therapeutics Investigational Trial Site
Decatur, IL United States
1.52miles
  Connect »